Guggenheim Has Lowered Expectations for Axsome Therapeutics (NASDAQ:AXSM) Stock Price

Axsome Therapeutics (NASDAQ:AXSM) had its target price decreased by research analysts at Guggenheim from $275.00 to $250.00 in a research note issued to investors on Tuesday, Benzinga reports. The firm currently has a “buy” rating on the stock. Guggenheim‘s target price indicates a potential upside of 73.40% from the stock’s current price.

A number of other research firms have also issued reports on AXSM. BMO Capital Markets initiated coverage on shares of Axsome Therapeutics in a research report on Monday, July 20th. They issued an “outperform” rating and a $310.00 price target for the company. Mizuho raised their price target on shares of Axsome Therapeutics from $306.00 to $316.00 and gave the stock an “outperform” rating in a report on Wednesday, August 12th. Deutsche Bank Aktiengesellschaft lowered their price objective on shares of Axsome Therapeutics from $280.00 to $267.00 and set a “buy” rating on the stock in a research report on Tuesday, September 29th. Needham & Company LLC upped their price objective on shares of Axsome Therapeutics from $267.00 to $268.00 and gave the company a “buy” rating in a research note on Tuesday, August 11th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Axsome Therapeutics in a research report on Thursday, October 15th. One analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Axsome Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $270.95.

Axsome Therapeutics Stock Up 6.0%

NASDAQ:AXSM opened at $144.18 on Tuesday. The business’s fifty day moving average price is $183.33 and its 200 day moving average price is $198.74. The firm has a market capitalization of $7.55 billion, a price-to-earnings ratio of -38.09 and a beta of 0.86. The company has a current ratio of 1.43, a quick ratio of 1.34 and a debt-to-equity ratio of 1.52. Axsome Therapeutics has a 1-year low of $123.00 and a 1-year high of $260.19.

Axsome Therapeutics (NASDAQ:AXSM) last announced its quarterly earnings data on Monday, November 2nd. The company reported ($0.25) EPS for the quarter, topping analysts’ consensus estimates of ($0.63) by $0.38. Axsome Therapeutics had a negative return on equity of 265.55% and a negative net margin of 24.68%. The firm had revenue of $259.69 million during the quarter, compared to analyst estimates of $249.19 million. During the same period last year, the company posted ($0.94) EPS. The business’s quarterly revenue was up 51.9% compared to the same quarter last year. On average, sell-side analysts forecast that Axsome Therapeutics will post -3.04 earnings per share for the current fiscal year.

Insider Transactions at Axsome Therapeutics

In other news, COO Mark Jacobson sold 10,000 shares of the firm’s stock in a transaction dated Thursday, September 3rd. The stock was sold at an average price of $208.65, for a total transaction of $2,086,500.00. Following the completion of the sale, the chief operating officer directly owned 10,000 shares of the company’s stock, valued at $2,086,500. This trade represents a 50.00% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Herriot Tabuteau sold 4,660 shares of Axsome Therapeutics stock in a transaction dated Thursday, August 6th. The shares were sold at an average price of $213.95, for a total value of $997,007.00. Following the sale, the chief executive officer owned 7,229 shares of the company’s stock, valued at approximately $1,546,644.55. This represents a 39.20% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 59,664 shares of company stock valued at $12,624,805 over the last ninety days. Company insiders own 20.60% of the company’s stock.

Institutional Trading of Axsome Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the business. BlackRock Inc. bought a new stake in Axsome Therapeutics in the second quarter worth approximately $759,695,000. Hillsdale Investment Management Inc. acquired a new position in shares of Axsome Therapeutics during the 1st quarter worth $9,019,000. OneDigital Investment Advisors LLC bought a new position in shares of Axsome Therapeutics during the 2nd quarter valued at $1,906,000. Baird Financial Group Inc. bought a new position in shares of Axsome Therapeutics during the 2nd quarter valued at $2,497,000. Finally, Lisanti Capital Growth LLC bought a new position in shares of Axsome Therapeutics during the 2nd quarter valued at $5,097,000. 81.49% of the stock is currently owned by institutional investors and hedge funds.

Trending Headlines about Axsome Therapeutics

Here are the key news stories impacting Axsome Therapeutics this week:

• Positive Sentiment: Axsome reported third-quarter revenue of $259.7 million, up 51.9% year over year and above the $249.2 million consensus estimate. Its adjusted loss of $0.25 per share was substantially narrower than the expected $0.63 loss and the year-ago loss of $0.94. Axsome Third-Quarter Results
• Positive Sentiment: Sales increased across Axsome’s key commercial brands, while management highlighted pipeline milestones expected in 2027. The earnings call also pointed to broader growth opportunities beyond the current product portfolio. Axsome Sales and Pipeline Update
• Neutral Sentiment: Axsome will participate in four healthcare investor conferences from November 9 through November 16. The events could provide updates on commercialization plans, clinical programs and future growth. Axsome Investor Conferences
• Negative Sentiment: Analysts lowered their price targets despite maintaining favorable ratings: Robert W. Baird cut its target to $220 from $246 while keeping an “outperform” rating, UBS reduced its target to $239 from $256, and Piper Sandler lowered its target to $235 from $238. The reductions signal more cautious expectations, although the targets remain well above the current trading level. Baird Axsome Price Target
• Negative Sentiment: Investor concerns center on AUVELITY’s slower-than-expected adoption for Alzheimer’s-related agitation. Recent growth appears to be driven more by prescriptions for depression in patients under 65 than by the newer Alzheimer’s opportunity, while some quarterly revenue benefit came from one-time items and improved gross-to-net dynamics rather than sustainable volume growth. Axsome Launch Concerns

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing therapies for central nervous system (CNS) disorders. Founded in 2012 and headquartered in New York, the company develops medicines for conditions with significant unmet medical needs, including depression, narcolepsy, excessive daytime sleepiness, and other neurological disorders.

Axsome’s commercial products include Auvelity (dextromethorphan and bupropion), an oral treatment approved in the United States for major depressive disorder in adults, and Sunosi (solriamfetol), a therapy for excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea.